How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration

Pat Furlong, John F P Bridges, Lawrence Charnas, Justin R. Fallon, Ryan Fischer, Kevin M. Flanigan, Timothy R. Franson, Neera Gulati, Craig M McDonald, Holly Peay, H. Lee Sweeney

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Among the challenges confronting patients with rare diseases is a dearth of treatment options. The development of safe and effective new therapies is hampered by challenges associated with conducting clinical trials in small populations. In this article, we describe how the Duchenne muscular dystrophy community-led by Parent Project Muscular Dystrophy-created a proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. This unprecedented undertaking involved a broad coalition of more than 80 stakeholders collaborating across nine time zones to produce a document in only 6 months. We hope that other rare disease communities and advocacy organizations can use our experience as a model for developing their own draft guidance documents.

Original languageEnglish (US)
Article number281
JournalOrphanet Journal of Rare Diseases
Volume10
Issue number1
DOIs
StatePublished - Jun 24 2015

Fingerprint

Patient Advocacy
United States Food and Drug Administration
Rare Diseases
Industry
Duchenne Muscular Dystrophy
Muscular Dystrophies
Clinical Trials
Organizations
Therapeutics
Population

Keywords

  • Advocacy
  • Clinical trial
  • Drug development
  • Duchenne muscular dystrophy
  • FDA
  • Industry guidance
  • Patient engagement
  • Public policy
  • Rare disease

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. / Furlong, Pat; Bridges, John F P; Charnas, Lawrence; Fallon, Justin R.; Fischer, Ryan; Flanigan, Kevin M.; Franson, Timothy R.; Gulati, Neera; McDonald, Craig M; Peay, Holly; Sweeney, H. Lee.

In: Orphanet Journal of Rare Diseases, Vol. 10, No. 1, 281, 24.06.2015.

Research output: Contribution to journalArticle

Furlong, Pat ; Bridges, John F P ; Charnas, Lawrence ; Fallon, Justin R. ; Fischer, Ryan ; Flanigan, Kevin M. ; Franson, Timothy R. ; Gulati, Neera ; McDonald, Craig M ; Peay, Holly ; Sweeney, H. Lee. / How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. In: Orphanet Journal of Rare Diseases. 2015 ; Vol. 10, No. 1.
@article{a2eceec8b1534e86abb2b80bf9a78cb9,
title = "How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration",
abstract = "Among the challenges confronting patients with rare diseases is a dearth of treatment options. The development of safe and effective new therapies is hampered by challenges associated with conducting clinical trials in small populations. In this article, we describe how the Duchenne muscular dystrophy community-led by Parent Project Muscular Dystrophy-created a proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. This unprecedented undertaking involved a broad coalition of more than 80 stakeholders collaborating across nine time zones to produce a document in only 6 months. We hope that other rare disease communities and advocacy organizations can use our experience as a model for developing their own draft guidance documents.",
keywords = "Advocacy, Clinical trial, Drug development, Duchenne muscular dystrophy, FDA, Industry guidance, Patient engagement, Public policy, Rare disease",
author = "Pat Furlong and Bridges, {John F P} and Lawrence Charnas and Fallon, {Justin R.} and Ryan Fischer and Flanigan, {Kevin M.} and Franson, {Timothy R.} and Neera Gulati and McDonald, {Craig M} and Holly Peay and Sweeney, {H. Lee}",
year = "2015",
month = "6",
day = "24",
doi = "10.1186/s13023-015-0281-2",
language = "English (US)",
volume = "10",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - How a patient advocacy group developed the first proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration

AU - Furlong, Pat

AU - Bridges, John F P

AU - Charnas, Lawrence

AU - Fallon, Justin R.

AU - Fischer, Ryan

AU - Flanigan, Kevin M.

AU - Franson, Timothy R.

AU - Gulati, Neera

AU - McDonald, Craig M

AU - Peay, Holly

AU - Sweeney, H. Lee

PY - 2015/6/24

Y1 - 2015/6/24

N2 - Among the challenges confronting patients with rare diseases is a dearth of treatment options. The development of safe and effective new therapies is hampered by challenges associated with conducting clinical trials in small populations. In this article, we describe how the Duchenne muscular dystrophy community-led by Parent Project Muscular Dystrophy-created a proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. This unprecedented undertaking involved a broad coalition of more than 80 stakeholders collaborating across nine time zones to produce a document in only 6 months. We hope that other rare disease communities and advocacy organizations can use our experience as a model for developing their own draft guidance documents.

AB - Among the challenges confronting patients with rare diseases is a dearth of treatment options. The development of safe and effective new therapies is hampered by challenges associated with conducting clinical trials in small populations. In this article, we describe how the Duchenne muscular dystrophy community-led by Parent Project Muscular Dystrophy-created a proposed draft guidance document for industry for submission to the U.S. Food and Drug Administration. This unprecedented undertaking involved a broad coalition of more than 80 stakeholders collaborating across nine time zones to produce a document in only 6 months. We hope that other rare disease communities and advocacy organizations can use our experience as a model for developing their own draft guidance documents.

KW - Advocacy

KW - Clinical trial

KW - Drug development

KW - Duchenne muscular dystrophy

KW - FDA

KW - Industry guidance

KW - Patient engagement

KW - Public policy

KW - Rare disease

UR - http://www.scopus.com/inward/record.url?scp=84948703784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948703784&partnerID=8YFLogxK

U2 - 10.1186/s13023-015-0281-2

DO - 10.1186/s13023-015-0281-2

M3 - Article

C2 - 26104810

AN - SCOPUS:84948703784

VL - 10

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 281

ER -